International Consensus Guideline on Small for Gestational Age: Etiology and Management From Infancy to Early Adulthood
Endocrine Reviews · 26 authors, 29 centres
AI SUMMARY
FIDELITY 92%
This summary was generated by AI from a single paper. It has not been reviewed by a clinician and is not clinical advice. Verify against the source before acting on it.
This international consensus guideline provides updated recommendations on the diagnosis, etiology, and management of small for gestational age (SGA) from infancy through early adulthood. It defines SGA as birth weight and/or length below −2 SDS for gestational age and emphasizes that excessive postnatal weight gain is a key risk factor for later cardiometabolic disease. Growth hormone treatment (0.033–0.067 mg/kg/day) is effective and safe for persistent short stature after SGA birth, with no long-term adverse cardiometabolic effects observed after cessation.
Full summary
3,127 CHARS
**Background:** Low birth weight, defined by the WHO as less than 2500 g, is associated with both short- and long-term consequences, including increased risk of type 2 diabetes and cardiometabolic disease. This international consensus guideline updates the 2007 consensus on small for gestational age (SGA), incorporating new insights into (epi)genetic causes, long-term consequences, and treatment options including gonadotropin-releasing hormone agonists (GnRHa) combined with growth hormone (GH) treatment.
**Methods:** The taskforce comprised 26 members including pediatric endocrinologists, clinical geneticists, and neonatologists, nominated by 10 international pediatric endocrine societies. A comprehensive literature search of PubMed, Embase, and Cochrane databases was conducted in December 2019 and updated in March 2022, reviewing 1300 articles. Three working groups addressed: 1) diagnosis and etiology, 2) consequences, and 3) clinical management. Recommendations were voted on using a system where A = full agreement, B = general agreement in favor, C = weak agreement, D = no agreement. Strength of recommendation was recorded as + (26–49%), ++ (50–69%), or +++ (≥70%).
**Key Results:** SGA is defined as birth weight and/or length below −2 SDS for gestational age. At least 90% of children born SGA show spontaneous catch-up growth into the normal height range, with 85% completing catch-up within the first 2 years. Children with height below −2 SDS at age 3 have a 7-fold increased risk of remaining short. Mortality risk is higher in SGA neonates, and approximately one-third experience hypoglycemia. Accelerated postnatal weight gain is identified as the key independent risk factor for later metabolic disease. GH treatment (0.033 mg/kg/day) induces catch-up growth with mean adult height gain of 1.25 SDS. Addition of 2 years of GnRHa treatment in children still short at puberty onset improves adult height by an average of 6.6 cm. Long-term follow-up (5–12 years after GH cessation) shows no adverse effects on insulin sensitivity, blood pressure, or lipid profiles compared to untreated controls. Genetic testing identifies pathogenic copy number variations in 15% and monogenic causes in up to 45% of short SGA children with syndromic features.
**Clinical Implications:** The guideline recommends using national growth charts for SGA classification, close monitoring of growth and weight trajectories in the first years of life, and avoiding excessive postnatal weight gain. Referral to a pediatric endocrinologist is indicated for persistent short stature (< −2.5 SDS at age 2 or < −2 SDS at age 3–4). GH treatment (0.033–0.067 mg/kg/day) is recommended for persistent short stature after ruling out other causes, with a starting dose of 0.033 mg/kg/day. Genetic testing should be considered in children with persistent short stature, dysmorphic features, or suspected syndromic conditions. Routine metabolic monitoring is only recommended for children with risk factors such as overweight, obesity, or family history. Upon GH discontinuation, counseling on healthy diet and lifestyle is advised.